-
1
-
-
83455236602
-
Trends in primary care antidepressant prescribing 1995-2007: A longitudinal population database analysis
-
Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. Br J Gen Pract 2011; 61(590): e565-72.
-
(2011)
Br J Gen Pract
, vol.61
, Issue.590
-
-
Lockhart, P.1
Guthrie, B.2
-
2
-
-
84857666179
-
Pharmacotherapy of anxiety disorders: A critical review
-
Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 2011; 13(4): 423-37.
-
(2011)
Dialogues Clin Neurosci
, vol.13
, Issue.4
, pp. 423-437
-
-
Koen, N.1
Stein, D.J.2
-
3
-
-
42949168966
-
Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: A meta-analysis
-
Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008; 111(5): 1175-82.
-
(2008)
Obstet Gynecol
, vol.111
, Issue.5
, pp. 1175-1182
-
-
Shah, N.R.1
Jones, J.B.2
Aperi, J.3
Shemtov, R.4
Karne, A.5
Borenstein, J.6
-
5
-
-
0030614953
-
Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac)
-
Ni YG, Miledi R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 1997; 94(5): 2036-40.
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, Issue.5
, pp. 2036-2040
-
-
Ni, Y.G.1
Miledi, R.2
-
7
-
-
66149149075
-
Pharmacology and therapeutic potential of sigma(1) receptor ligands
-
Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 2008; 6(4): 344-66.
-
(2008)
Curr Neuropharmacol
, vol.6
, Issue.4
, pp. 344-366
-
-
Cobos, E.J.1
Entrena, J.M.2
Nieto, F.R.3
Cendan, C.M.4
Del Pozo, E.5
-
8
-
-
84856639838
-
Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action
-
Zhong H, Haddjeri N, Sanchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 2012; 219(1): 1-13.
-
(2012)
Psychopharmacology (Berl)
, vol.219
, Issue.1
, pp. 1-13
-
-
Zhong, H.1
Haddjeri, N.2
Sanchez, C.3
-
9
-
-
0037330603
-
Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: Exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition
-
Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 2003; 64(2): 110-1.
-
(2003)
J Clin Psychiatry
, vol.64
, Issue.2
, pp. 110-111
-
-
Stahl, S.M.1
-
10
-
-
0037362361
-
Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: Both dopamine and norepinephrine increase in prefrontal cortex
-
Stahl SM. Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. J Clin Psychiatry 2003; 64(3): 230-1.
-
(2003)
J Clin Psychiatry
, vol.64
, Issue.3
, pp. 230-231
-
-
Stahl, S.M.1
-
11
-
-
0037262304
-
Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: Norepinephrine transporters regulate dopamine
-
Stahl SM. Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry 2003; 64(1): 4-5.
-
(2003)
J Clin Psychiatry
, vol.64
, Issue.1
, pp. 4-5
-
-
Stahl, S.M.1
-
12
-
-
67649405195
-
Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors
-
Briley M, Moret C. Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr 2008; 13(7 Suppl 11): 22-6.
-
(2008)
CNS Spectr
, vol.13
, Issue.7 SUPPL. 11
, pp. 22-26
-
-
Briley, M.1
Moret, C.2
-
13
-
-
0029891688
-
Dose-response relationship with venlafaxine
-
discussion 6S-8S
-
Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol 1996; 16(3 Suppl 2): 21S-6S; discussion 6S-8S.
-
(1996)
J Clin Psychopharmacol
, vol.16
, Issue.3 SUPPL. 2
-
-
Kelsey, J.E.1
-
14
-
-
11144231468
-
The role of venlafaxine in the treatment of obsessive-compulsive disorder
-
Phelps NJ, Cates ME. The role of venlafaxine in the treatment of obsessive-compulsive disorder. Ann Pharmacother 2005; 39(1): 136-40.
-
(2005)
Ann Pharmacother
, vol.39
, Issue.1
, pp. 136-140
-
-
Phelps, N.J.1
Cates, M.E.2
-
15
-
-
34250368104
-
Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder
-
Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder. Expert Rev Neurother 2007; 7(6): 603-15.
-
(2007)
Expert Rev Neurother
, vol.7
, Issue.6
, pp. 603-615
-
-
Pae, C.U.1
Lim, H.K.2
Ajwani, N.3
Lee, C.4
Patkar, A.A.5
-
16
-
-
81855205290
-
Desvenlafaxine in the treatment of major depressive disorder
-
Pae CU. Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother 2011; 12(18): 2923-8.
-
(2011)
Expert Opin Pharmacother
, vol.12
, Issue.18
, pp. 2923-2928
-
-
Pae, C.U.1
-
17
-
-
65849379466
-
Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system
-
Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 2008; 14(6): 368-78.
-
(2008)
J Psychiatr Pract
, vol.14
, Issue.6
, pp. 368-378
-
-
Preskorn, S.H.1
Nichols, A.I.2
Paul, J.3
Patroneva, A.L.4
Helzner, E.C.5
Guico-Pabia, C.J.6
-
18
-
-
80055111117
-
Duloxetine in the treatment of depression: An overview
-
Monteleone F, Caputo M, Tecce MF, Capasso A. Duloxetine in the treatment of depression: an overview. Cent Nerv Syst Agents Med Chem 2011; 11(3): 174-83.
-
(2011)
Cent Nerv Syst Agents Med Chem
, vol.11
, Issue.3
, pp. 174-183
-
-
Monteleone, F.1
Caputo, M.2
Tecce, M.F.3
Capasso, A.4
-
19
-
-
84860612593
-
Treatments for diabetic neuropathy
-
Bril V. Treatments for diabetic neuropathy. J Peripher Nerv Syst 2012; 17 Suppl 2:22-7.
-
(2012)
J Peripher Nerv Syst
, vol.17
, Issue.SUPPL. 2
, pp. 22-27
-
-
Bril, V.1
-
20
-
-
84859089938
-
The role of antidepressants in the management of fibromyalgia syndrome: A systematic review and meta-analysis
-
Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012; 26(4): 297-307.
-
(2012)
CNS Drugs
, vol.26
, Issue.4
, pp. 297-307
-
-
Hauser, W.1
Wolfe, F.2
Tolle, T.3
Uceyler, N.4
Sommer, C.5
-
21
-
-
84856893689
-
A systematic review of duloxetine for osteoarthritic pain: What is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
-
Citrome L, Weiss-Citrome A. A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Postgrad Med 2012; 124(1): 83-93.
-
(2012)
Postgrad Med
, vol.124
, Issue.1
, pp. 83-93
-
-
Citrome, L.1
Weiss-Citrome, A.2
-
22
-
-
80955150217
-
Milnacipran: A unique antidepressant?
-
Kasper S, Pail G. Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat 2010; 6: 23-31.
-
(2010)
Neuropsychiatr Dis Treat
, vol.6
, pp. 23-31
-
-
Kasper, S.1
Pail, G.2
-
23
-
-
84876718762
-
Levominacipran in the treatment of major depressive disorer: An analysis of efficacy data from 2 pahse III studies
-
May 8; Philadelphia, PA
-
Bose A, Gommoll C, Li H, Rut A. Levominacipran in the treatment of major depressive disorer: an analysis of efficacy data from 2 pahse III studies. American Psychiatric Association Annual Meeting; May 8; Philadelphia, PA2012.
-
(2012)
American Psychiatric Association Annual Meeting
-
-
Bose, A.1
Gommoll, C.2
Li, H.3
Rut, A.4
-
24
-
-
80052145818
-
Quetiapine extended release: Adjunctive treatment in major depressive disorder
-
Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs 2011; 25(9): 803-13.
-
(2011)
CNS Drugs
, vol.25
, Issue.9
, pp. 803-813
-
-
Sanford, M.1
-
25
-
-
84859940784
-
Quetiapine: A review of its use in the management of bipolar depression
-
Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012; 26(5): 435-60.
-
(2012)
CNS Drugs
, vol.26
, Issue.5
, pp. 435-460
-
-
Sanford, M.1
Keating, G.M.2
-
26
-
-
79955889045
-
A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder
-
Pangallo B, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res 2011; 45(6): 748-55.
-
(2011)
J Psychiatr Res
, vol.45
, Issue.6
, pp. 748-755
-
-
Pangallo, B.1
Dellva, M.A.2
D'Souza, D.N.3
Essink, B.4
Russell, J.5
Goldberger, C.6
-
27
-
-
33846003865
-
Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent
-
Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006; 12(3-4): 178-207.
-
(2006)
CNS Drug Rev
, vol.12
, Issue.3-4
, pp. 178-207
-
-
Dwoskin, L.P.1
Rauhut, A.S.2
King-Pospisil, K.A.3
Bardo, M.T.4
-
28
-
-
0036367835
-
Bupropion occupancy of the dopamine transporter is low during clinical treatment
-
Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002; 163(1): 102-5.
-
(2002)
Psychopharmacology (Berl)
, vol.163
, Issue.1
, pp. 102-105
-
-
Meyer, J.H.1
Goulding, V.S.2
Wilson, A.A.3
Hussey, D.4
Christensen, B.K.5
Houle, S.6
-
29
-
-
2442457724
-
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study
-
Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004; 161(5): 826-35.
-
(2004)
Am J Psychiatry
, vol.161
, Issue.5
, pp. 826-835
-
-
Meyer, J.H.1
Wilson, A.A.2
Sagrati, S.3
-
30
-
-
77949281313
-
Regulation of the dopamine transporter: Aspects relevant to psychostimulant drugs of abuse
-
Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann N Y Acad Sci 2010; 1187: 316-40.
-
(2010)
Ann N Y Acad Sci
, vol.1187
, pp. 316-340
-
-
Schmitt, K.C.1
Reith, M.E.2
-
31
-
-
0034966465
-
[(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy
-
Fowler JS, Volkow ND, Wang GJ, Gatley SJ, Logan J. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001; 28(5): 561-72.
-
(2001)
Nucl Med Biol
, vol.28
, Issue.5
, pp. 561-572
-
-
Fowler, J.S.1
Volkow, N.D.2
Wang, G.J.3
Gatley, S.J.4
Logan, J.5
-
32
-
-
0028787766
-
Bupropion: A review of its mechanism of antidepressant activity
-
Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56(9): 395-401.
-
(1995)
J Clin Psychiatry
, vol.56
, Issue.9
, pp. 395-401
-
-
Ascher, J.A.1
Cole, J.O.2
Colin, J.N.3
-
33
-
-
79960016570
-
Star-D: Lessons learned and future implications
-
Rush AJ. Star-D: lessons learned and future implications. Depress Anxiety 2011; 28(7): 521-4.
-
(2011)
Depress Anxiety
, vol.28
, Issue.7
, pp. 521-524
-
-
Rush, A.J.1
-
34
-
-
33751338530
-
Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report
-
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905-17.
-
(2006)
Am J Psychiatry
, vol.163
, Issue.11
, pp. 1905-1917
-
-
Rush, A.J.1
Trivedi, M.H.2
Wisniewski, S.R.3
-
35
-
-
84858153468
-
Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial
-
Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 2012; 125(4): 342-8.
-
(2012)
Acta Psychiatr Scand
, vol.125
, Issue.4
, pp. 342-348
-
-
Bech, P.1
Fava, M.2
Trivedi, M.H.3
Wisniewski, S.R.4
Rush, A.J.5
-
36
-
-
80054867307
-
The efficacy and tolerability of bupropion in the treatment of major depressive disorder
-
Moreira R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Investig 2011; 31 Suppl 1: 5-17.
-
(2011)
Clin Drug Investig
, vol.31
, Issue.SUPPL. 1
, pp. 5-17
-
-
Moreira, R.1
-
37
-
-
70450203499
-
Prospect of a dopamine contribution in the next generation of antidepressant drugs: The triple reuptake inhibitors
-
Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009; 10(11): 1069-84.
-
(2009)
Curr Drug Targets
, vol.10
, Issue.11
, pp. 1069-1084
-
-
Guiard, B.P.1
El Mansari, M.2
Blier, P.3
-
38
-
-
79960381632
-
Triple reuptake inhibitors for treating subtypes of major depressive disorder: The monoamine hypothesis revisited
-
Prins J, Olivier B, Korte SM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin Investig Drugs 2011; 20(8): 1107-30.
-
(2011)
Expert Opin Investig Drugs
, vol.20
, Issue.8
, pp. 1107-1130
-
-
Prins, J.1
Olivier, B.2
Korte, S.M.3
-
39
-
-
33748077457
-
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor
-
Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 2006; 12(2): 123-34.
-
(2006)
CNS Drug Rev
, vol.12
, Issue.2
, pp. 123-134
-
-
Skolnick, P.1
Krieter, P.2
Tizzano, J.3
-
40
-
-
81855211117
-
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, doubleblind, placebo-controlled trial
-
Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, doubleblind, placebo-controlled trial. J Psychiatr Res 2012; 46(1): 64-71.
-
(2012)
J Psychiatr Res
, vol.46
, Issue.1
, pp. 64-71
-
-
Tran, P.1
Skolnick, P.2
Czobor, P.3
-
41
-
-
0029885576
-
Adrenoceptors and serotonin receptor function: Relevance to antidepressant mechanisms of action
-
Potter WZ. Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. J Clin Psychiatry 1996; 57 Suppl 4: 4-8.
-
(1996)
J Clin Psychiatry
, vol.57
, Issue.SUPPL. 4
, pp. 4-8
-
-
Potter, W.Z.1
-
42
-
-
37049007217
-
Presynaptic autoreceptors regulating transmitter release
-
Langer SZ. Presynaptic autoreceptors regulating transmitter release. Neurochem Int 2008; 52(1-2): 26-30.
-
(2008)
Neurochem Int
, vol.52
, Issue.1-2
, pp. 26-30
-
-
Langer, S.Z.1
-
43
-
-
79958731767
-
Review of the use of mirtazapine in the treatment of depression
-
Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011; 12(10): 1623-32.
-
(2011)
Expert Opin Pharmacother
, vol.12
, Issue.10
, pp. 1623-1632
-
-
Benjamin, S.1
Doraiswamy, P.M.2
-
44
-
-
79951656434
-
Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: An 8-week open-label randomised paroxetine-controlled trial
-
Kim JE, Yoon SJ, Kim J, et al. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract 2011; 65(3): 323-9.
-
(2011)
Int J Clin Pract
, vol.65
, Issue.3
, pp. 323-329
-
-
Kim, J.E.1
Yoon, S.J.2
Kim, J.3
-
45
-
-
0030915142
-
A comparison of the physicochemical and biological properties of mirtazapine and mianserin
-
Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V. A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol 1997; 49(4): 403-11.
-
(1997)
J Pharm Pharmacol
, vol.49
, Issue.4
, pp. 403-411
-
-
Kelder, J.1
Funke, C.2
de Boer, T.3
Delbressine, L.4
Leysen, D.5
Nickolson, V.6
-
46
-
-
0032510218
-
Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex
-
Dawson LA, Nguyen HQ. Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol 1998; 345(1): 41-6.
-
(1998)
Eur J Pharmacol
, vol.345
, Issue.1
, pp. 41-46
-
-
Dawson, L.A.1
Nguyen, H.Q.2
-
47
-
-
84930482645
-
Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
-
Singh M, Schwartz TL. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr Dis Treat 2012; 8: 123-30.
-
(2012)
Neuropsychiatr Dis Treat
, vol.8
, pp. 123-130
-
-
Singh, M.1
Schwartz, T.L.2
-
48
-
-
0030957585
-
EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties
-
Bartoszyk GD, Hegenbart R, Ziegler H. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 1997; 322(2-3): 147-53.
-
(1997)
Eur J Pharmacol
, vol.322
, Issue.2-3
, pp. 147-153
-
-
Bartoszyk, G.D.1
Hegenbart, R.2
Ziegler, H.3
-
49
-
-
0033827059
-
Drug action at the 5-HT(1A) receptor in vivo: Autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635
-
Rabiner EA, Gunn RN, Wilkins MR, et al. Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl Med Biol 2000; 27(5): 509-13.
-
(2000)
Nucl Med Biol
, vol.27
, Issue.5
, pp. 509-513
-
-
Rabiner, E.A.1
Gunn, R.N.2
Wilkins, M.R.3
-
50
-
-
33947326248
-
Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression
-
de Paulis T. Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs 2007; 10(3): 193-201.
-
(2007)
IDrugs
, vol.10
, Issue.3
, pp. 193-201
-
-
de Paulis, T.1
-
51
-
-
34548617702
-
Augmentation strategies for treatment-resistant depression: A literature review
-
Carvalho AF, Cavalcante JL, Castelo MS, Lima MC. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 2007; 32(5): 415-28.
-
(2007)
J Clin Pharm Ther
, vol.32
, Issue.5
, pp. 415-428
-
-
Carvalho, A.F.1
Cavalcante, J.L.2
Castelo, M.S.3
Lima, M.C.4
-
52
-
-
73849088753
-
Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
-
Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 2009; 18(11): 1753-64.
-
(2009)
Expert Opin Investig Drugs
, vol.18
, Issue.11
, pp. 1753-1764
-
-
Khan, A.1
-
53
-
-
0032958811
-
Effects of SSRIs on sexual function: A critical review
-
Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19(1): 67-85.
-
(1999)
J Clin Psychopharmacol
, vol.19
, Issue.1
, pp. 67-85
-
-
Rosen, R.C.1
Lane, R.M.2
Menza, M.3
-
54
-
-
84997941890
-
Vilazodone: A brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor
-
Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Therapeutic Advances in Psychopharmacology 2011; 1(3): 81-7.
-
(2011)
Therapeutic Advances in Psychopharmacology
, vol.1
, Issue.3
, pp. 81-87
-
-
Schwartz, T.L.1
Siddiqui, U.A.2
Stahl, S.M.3
-
55
-
-
0028408335
-
Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders
-
Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4(4): 331-55.
-
(1994)
Drugs Aging
, vol.4
, Issue.4
, pp. 331-355
-
-
Haria, M.1
Fitton, A.2
McTavish, D.3
-
56
-
-
78650569849
-
Second-generation antipsychotics in major depressive disorder: Update and clinical perspective
-
Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011; 24(1): 10-7.
-
(2011)
Curr Opin Psychiatry
, vol.24
, Issue.1
, pp. 10-17
-
-
Chen, J.1
Gao, K.2
Kemp, D.E.3
-
57
-
-
33846426067
-
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
-
Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007; 113(2): 296-320.
-
(2007)
Pharmacol Ther
, vol.113
, Issue.2
, pp. 296-320
-
-
Alex, K.D.1
Pehek, E.A.2
-
58
-
-
51149117395
-
Olanzapine/fluoxetine combination for treatmentresistant depression: Efficacy and clinical utility
-
Dodd S, Berk M. Olanzapine/fluoxetine combination for treatmentresistant depression: efficacy and clinical utility. Expert Rev Neurother 2008; 8(9): 1299-306.
-
(2008)
Expert Rev Neurother
, vol.8
, Issue.9
, pp. 1299-1306
-
-
Dodd, S.1
Berk, M.2
-
59
-
-
77956590945
-
Quetiapine: Novel uses in the treatment of depressive and anxiety disorders
-
Ravindran AV, Al-Subaie A, Abraham G. Quetiapine: novel uses in the treatment of depressive and anxiety disorders. Expert Opin Investig Drugs 2010; 19(10): 1187-204.
-
(2010)
Expert Opin Investig Drugs
, vol.19
, Issue.10
, pp. 1187-1204
-
-
Ravindran, A.V.1
Al-Subaie, A.2
Abraham, G.3
-
60
-
-
84860741260
-
Asenapine: A clinical review of a secondgeneration antipsychotic
-
Stoner SC, Pace HA. Asenapine: a clinical review of a secondgeneration antipsychotic. Clin Ther 2012; 34(5): 1023-40.
-
(2012)
Clin Ther
, vol.34
, Issue.5
, pp. 1023-1040
-
-
Stoner, S.C.1
Pace, H.A.2
-
61
-
-
1842764851
-
GABAergic modulation of 5-HT7 receptor-mediated effects on 5-HT efflux in the guineapig dorsal raphe nucleus
-
Roberts C, Thomas DR, Bate ST, Kew JN. GABAergic modulation of 5-HT7 receptor-mediated effects on 5-HT efflux in the guineapig dorsal raphe nucleus. Neuropharmacology 2004; 46(7): 935-41.
-
(2004)
Neuropharmacology
, vol.46
, Issue.7
, pp. 935-941
-
-
Roberts, C.1
Thomas, D.R.2
Bate, S.T.3
Kew, J.N.4
-
62
-
-
79954597841
-
Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy
-
Mnie-Filali O, Faure C, Lambas-Senas L, et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011; 36(6): 1275-88.
-
(2011)
Neuropsychopharmacology
, vol.36
, Issue.6
, pp. 1275-1288
-
-
Mnie-Filali, O.1
Faure, C.2
Lambas-Senas, L.3
-
63
-
-
84867885144
-
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
-
Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012; 28(10): 1717-24.
-
(2012)
Curr Med Res Opin
, vol.28
, Issue.10
, pp. 1717-1724
-
-
Baldwin, D.S.1
Hansen, T.2
Florea, I.3
-
64
-
-
84863403855
-
Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder
-
Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012; 340(3): 666-75.
-
(2012)
J Pharmacol Exp Ther
, vol.340
, Issue.3
, pp. 666-675
-
-
Mork, A.1
Pehrson, A.2
Brennum, L.T.3
-
65
-
-
84873525387
-
Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study
-
Pehrson AL, Cremers T, Betry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 2012.
-
(2012)
Eur Neuropsychopharmacol
-
-
Pehrson, A.L.1
Cremers, T.2
Betry, C.3
-
66
-
-
84887319234
-
A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder
-
Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2012: 1-9.
-
(2012)
Int J Neuropsychopharmacol
, pp. 1-9
-
-
Jain, R.1
Mahableshwarkar, A.R.2
Jacobsen, P.L.3
Chen, Y.4
Thase, M.E.5
-
67
-
-
0034666574
-
The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy
-
Moret C, Briley M. The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 2000; 404(1-2): 1-12.
-
(2000)
Eur J Pharmacol
, vol.404
, Issue.1-2
, pp. 1-12
-
-
Moret, C.1
Briley, M.2
-
68
-
-
77950445050
-
The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target?
-
Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J Psychopharmacol 2010; 24(4): 455-69.
-
(2010)
J Psychopharmacol
, vol.24
, Issue.4
, pp. 455-469
-
-
Rajkumar, R.1
Mahesh, R.2
-
69
-
-
84858966700
-
Emerging drugs for major depressive disorder
-
Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 2012; 17(1): 105-26.
-
(2012)
Expert Opin Emerg Drugs
, vol.17
, Issue.1
, pp. 105-126
-
-
Connolly, K.R.1
Thase, M.E.2
|